Difficulty: Medium
Average Score: 82%
Practice
Which of the following hypnotic drugs is more likely to cause rebound insomnia upon abrupt discontinuation?
Correct answer
B
Rationale
In this scenario, the correct answer is option B) Triazolam. Triazolam is a short-acting benzodiazepine commonly used as a hypnotic due to its quick onset of action. It is more likely to cause rebound insomnia upon abrupt discontinuation because of its short half-life and potent effects on the central nervous system. Abruptly stopping Triazolam can lead to a rapid withdrawal of the drug from the body, resulting in a resurgence of insomnia symptoms, known as rebound insomnia.
Option A) Zaleplon is less likely to cause rebound insomnia compared to Triazolam as it has a shorter half-life and is generally well-tolerated with less potential for withdrawal symptoms.
Option C) Phenobarbital is a long-acting barbiturate that is more commonly associated with tolerance, dependence, and withdrawal symptoms, rather than rebound insomnia specifically.
Option D) Chloral hydrate, an older sedative-hypnotic agent, is also less likely to cause rebound insomnia compared to Triazolam due to its different mechanism of action and pharmacokinetics.
In an educational context, understanding the pharmacological properties of different hypnotic drugs is crucial for healthcare professionals to make informed decisions regarding the treatment of insomnia in clients across the lifespan. Knowing which drugs are more likely to cause rebound symptoms upon discontinuation can help in managing patient care effectively and ensuring the best outcomes for clients.
Option A) Zaleplon is less likely to cause rebound insomnia compared to Triazolam as it has a shorter half-life and is generally well-tolerated with less potential for withdrawal symptoms.
Option C) Phenobarbital is a long-acting barbiturate that is more commonly associated with tolerance, dependence, and withdrawal symptoms, rather than rebound insomnia specifically.
Option D) Chloral hydrate, an older sedative-hypnotic agent, is also less likely to cause rebound insomnia compared to Triazolam due to its different mechanism of action and pharmacokinetics.
In an educational context, understanding the pharmacological properties of different hypnotic drugs is crucial for healthcare professionals to make informed decisions regarding the treatment of insomnia in clients across the lifespan. Knowing which drugs are more likely to cause rebound symptoms upon discontinuation can help in managing patient care effectively and ensuring the best outcomes for clients.